Selective antitumor activity of Tumor Treating Fields (TTFields) involving molecular factors in cancer cells and tumor microenvironment

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2025-09-30 DOI:10.1016/j.tranon.2025.102556

Ilaria Fuso Nerini , Rosy Amodeo , Maurizio D’Incalci , Monica Lupi

{"title":"Selective antitumor activity of Tumor Treating Fields (TTFields) involving molecular factors in cancer cells and tumor microenvironment","authors":"Ilaria Fuso Nerini , Rosy Amodeo , Maurizio D’Incalci , Monica Lupi","doi":"10.1016/j.tranon.2025.102556","DOIUrl":null,"url":null,"abstract":"<div><div>The local application of low-intensity electric fields at intermediate frequencies (Tumor Treating Fields – TTFields) has emerged as an effective anticancer treatment in conjunction with chemotherapy and immunotherapy for several solid tumors. Despite this progress, the phenotypic and genetic determinants underlying tumor sensitivity to TTFields remain largely unexplored, representing a critical gap in our understanding.</div><div>This review provides a comprehensive analysis of preclinical and translational studies describing the cellular factors that influence the anticancer properties of TTFields. An overview of recent omics studies on the complex cellular and molecular processes initiated by TTFields has revealed important mechanisms of action that warrant further investigation for their therapeutic potential.</div><div>The goal is to identify effects that can be leveraged to develop rational, synergistic co-treatments with anticancer agents that have complementary modes of action. In particular, the ability of TTFields to modulate the tumor microenvironment and reverse the local and systemic immunosuppression could represent a promising strategy to enhance the efficacy of immunotherapy across different tumor types.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"62 ","pages":"Article 102556"},"PeriodicalIF":5.0000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523325002876","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The local application of low-intensity electric fields at intermediate frequencies (Tumor Treating Fields – TTFields) has emerged as an effective anticancer treatment in conjunction with chemotherapy and immunotherapy for several solid tumors. Despite this progress, the phenotypic and genetic determinants underlying tumor sensitivity to TTFields remain largely unexplored, representing a critical gap in our understanding.

This review provides a comprehensive analysis of preclinical and translational studies describing the cellular factors that influence the anticancer properties of TTFields. An overview of recent omics studies on the complex cellular and molecular processes initiated by TTFields has revealed important mechanisms of action that warrant further investigation for their therapeutic potential.

The goal is to identify effects that can be leveraged to develop rational, synergistic co-treatments with anticancer agents that have complementary modes of action. In particular, the ability of TTFields to modulate the tumor microenvironment and reverse the local and systemic immunosuppression could represent a promising strategy to enhance the efficacy of immunotherapy across different tumor types.

Abstract Image

查看原文本刊更多论文

肿瘤治疗场（TTFields）的选择性抗肿瘤活性，涉及肿瘤细胞和肿瘤微环境中的分子因子。

局部应用中频低强度电场（肿瘤治疗场- TTFields）已成为结合化疗和免疫治疗几种实体瘤的有效抗癌治疗方法。尽管取得了这一进展，但肿瘤对TTFields敏感性的表型和遗传决定因素在很大程度上仍未被探索，这代表了我们理解中的一个关键空白。这篇综述提供了临床前和转化研究的综合分析，描述了影响TTFields抗癌特性的细胞因素。最近对TTFields发起的复杂细胞和分子过程的组学研究概述揭示了重要的作用机制，值得进一步研究其治疗潜力。目标是确定可用于开发具有互补作用模式的抗癌药物的合理、协同联合治疗的效应。特别是，TTFields调节肿瘤微环境和逆转局部和全身免疫抑制的能力可能代表了一种有希望的策略，可以提高不同肿瘤类型的免疫治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.